{"name":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","slug":"centre-de-recherche-de-l-institut-universitaire-de-cardiologie-et-de-pneumologie","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"Atorvastatin-esomeprazole","genericName":"Atorvastatin-esomeprazole","slug":"atorvastatin-esomeprazole","indication":"Hyperlipidemia with concurrent need for gastric acid suppression","status":"marketed"},{"name":"Atorvastatin-omeprazole","genericName":"Atorvastatin-omeprazole","slug":"atorvastatin-omeprazole","indication":"Hypercholesterolemia with concurrent need for gastric acid suppression","status":"marketed"},{"name":"Rivaroxaban, dabigatran, apixaban, or edoxaban","genericName":"Rivaroxaban, dabigatran, apixaban, or edoxaban","slug":"rivaroxaban-dabigatran-apixaban-or-edoxaban","indication":"Atrial fibrillation for stroke prevention","status":"marketed"},{"name":"Rosuvastatin-omeprazole","genericName":"Rosuvastatin-omeprazole","slug":"rosuvastatin-omeprazole","indication":"Hypercholesterolemia with elevated cardiovascular risk in patients requiring gastric acid suppression","status":"marketed"},{"name":"Rosuvastatin-pantoprazole","genericName":"Rosuvastatin-pantoprazole","slug":"rosuvastatin-pantoprazole","indication":"Hypercholesterolemia with concurrent need for gastric acid suppression","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Atorvastatin-pantoprazole","genericName":"Atorvastatin-pantoprazole","slug":"atorvastatin-pantoprazole","indication":"Other","status":"marketed"},{"name":"Atorvastatin-ranitidine","genericName":"Atorvastatin-ranitidine","slug":"atorvastatin-ranitidine","indication":"Other","status":"marketed"},{"name":"Rosuvastatin-esomeprazole","genericName":"Rosuvastatin-esomeprazole","slug":"rosuvastatin-esomeprazole","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Rosuvastatin-ranitidine","genericName":"Rosuvastatin-ranitidine","slug":"rosuvastatin-ranitidine","indication":"Hypercholesterolemia with gastrointestinal intolerance or risk","status":"marketed"}]}],"pipeline":[{"name":"Rosuvastatin-ranitidine","genericName":"Rosuvastatin-ranitidine","slug":"rosuvastatin-ranitidine","phase":"marketed","mechanism":"This is a fixed-dose combination of rosuvastatin (a statin that lowers cholesterol) and ranitidine (an H2-receptor antagonist that reduces stomach acid).","indications":["Hypercholesterolemia with gastrointestinal intolerance or risk"],"catalyst":""},{"name":"Atorvastatin-esomeprazole","genericName":"Atorvastatin-esomeprazole","slug":"atorvastatin-esomeprazole","phase":"marketed","mechanism":"This combination drug lowers cholesterol by inhibiting HMG-CoA reductase (atorvastatin) while reducing gastric acid secretion by blocking the proton pump (esomeprazole).","indications":["Hyperlipidemia with concurrent need for gastric acid suppression","Cardiovascular disease prevention in patients at risk for statin-induced gastrointestinal adverse effects"],"catalyst":""},{"name":"Atorvastatin-omeprazole","genericName":"Atorvastatin-omeprazole","slug":"atorvastatin-omeprazole","phase":"marketed","mechanism":"This is a fixed-dose combination of atorvastatin (a statin that lowers cholesterol) and omeprazole (a proton pump inhibitor that reduces stomach acid).","indications":["Hypercholesterolemia with concurrent need for gastric acid suppression","Cardiovascular risk reduction in patients requiring proton pump inhibitor therapy"],"catalyst":""},{"name":"Atorvastatin-pantoprazole","genericName":"Atorvastatin-pantoprazole","slug":"atorvastatin-pantoprazole","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Atorvastatin-ranitidine","genericName":"Atorvastatin-ranitidine","slug":"atorvastatin-ranitidine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rivaroxaban, dabigatran, apixaban, or edoxaban","genericName":"Rivaroxaban, dabigatran, apixaban, or edoxaban","slug":"rivaroxaban-dabigatran-apixaban-or-edoxaban","phase":"marketed","mechanism":"These are direct oral anticoagulants (DOACs) that inhibit specific clotting factors to prevent blood clot formation.","indications":["Atrial fibrillation for stroke prevention","Deep vein thrombosis (DVT) treatment and prevention","Pulmonary embolism (PE) treatment and prevention","Acute coronary syndrome (select agents)"],"catalyst":""},{"name":"Rosuvastatin-esomeprazole","genericName":"Rosuvastatin-esomeprazole","slug":"rosuvastatin-esomeprazole","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rosuvastatin-omeprazole","genericName":"Rosuvastatin-omeprazole","slug":"rosuvastatin-omeprazole","phase":"marketed","mechanism":"This combination drug reduces cholesterol via HMG-CoA reductase inhibition (rosuvastatin) while simultaneously reducing gastric acid secretion (omeprazole) to protect the gastrointestinal tract.","indications":["Hypercholesterolemia with elevated cardiovascular risk in patients requiring gastric acid suppression"],"catalyst":""},{"name":"Rosuvastatin-pantoprazole","genericName":"Rosuvastatin-pantoprazole","slug":"rosuvastatin-pantoprazole","phase":"marketed","mechanism":"This combination drug lowers cholesterol via HMG-CoA reductase inhibition (rosuvastatin) while reducing gastric acid secretion via proton pump inhibition (pantoprazole).","indications":["Hypercholesterolemia with concurrent need for gastric acid suppression","Cardiovascular risk reduction in patients requiring proton pump inhibitor therapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9jNk9EM0VFcWNkYTduLW5vN2FDcVZyWHZOZjFRc3NrNlZzOHBxYTliWTRfamRPZEl0cGliemdScm9ndUdJSHJieFQzQ3VTQnNfRXlj?oc=5","date":"2025-06-05","type":"earnings","source":"National Institutes of Health (.gov)","summary":"A flexible machine learning Mendelian randomization estimator applied to predict the safety and efficacy of sclerostin inhibition - National Institutes of Health (.gov)","headline":"A flexible machine learning Mendelian randomization estimator applied to predict the safety and efficacy of sclerostin i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPdGtPS2pRNE94OVFHb000WXBvMWpnY2NxMlMzcFp1MTBHV0taM0hINXVNcTdscWtxS0NQQ0RDNmdBZWFOY3RvSFJpbTJGbERuRDBVVUVPS25qVG1SS0l3cF9iYTh0bzhfRDhQYWpWQU5QZVdraUFlMHp0NmhtWTNlanY1Vy1hb1A4ZnAtaGJYYW5DSlRwQkE?oc=5","date":"2024-02-15","type":"pipeline","source":"Frontiers","summary":"Plasma IGFBP-2 levels reveal heterogeneity in hepatic fat content in adults with excess visceral adiposity - Frontiers","headline":"Plasma IGFBP-2 levels reveal heterogeneity in hepatic fat content in adults with excess visceral adiposity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5wbDZPOFBWNjJYVGdVU3VxeXpTcXI3UVJqdGd5T2JZN2M1Z2tBdGFzSk5KLXhDWW5hcVBXSmZZcnhoOVBBWERQVHJIWGR2b2dWbE9Ta0pQZHI2UGpxQkcw?oc=5","date":"2023-07-26","type":"pipeline","source":"nature.com","summary":"N -eicosapentaenoyl-ethanolamine decreases the proliferation of psoriatic keratinocytes in a reconstructed psoriatic skin model - nature.com","headline":"N -eicosapentaenoyl-ethanolamine decreases the proliferation of psoriatic keratinocytes in a reconstructed psoriatic ski","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9kQ0labXB4ZEtaTVg5cjJEcU9TaVB0M0RIOVRLMmVoUzVIRW5mNm5xV3BzWThZQnVYdDhUY05WczlESExTSl92ckp4bndaM2FFZHdQV3NqS3NCenpudklF?oc=5","date":"2022-01-11","type":"pipeline","source":"nature.com","summary":"The transcription factor hepatocyte nuclear factor 4A acts in the intestine to promote white adipose tissue energy storage - nature.com","headline":"The transcription factor hepatocyte nuclear factor 4A acts in the intestine to promote white adipose tissue energy stora","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1xbE01UW1hUFUtVy1TRDR5S3lOV3Axa1ZOYkx5ZExyQ1pQS3h2TjlORVctZU9PZTA0TGl6VlR2MUNlY24tWi1SOUk2R1hwcFhzN194cG4zcU5PY3VDWnJB?oc=5","date":"2021-07-19","type":"trial","source":"nature.com","summary":"Meta-regression of randomized control trials with antithrombotics: weak correlation between net clinical benefit and all cause-mortality - nature.com","headline":"Meta-regression of randomized control trials with antithrombotics: weak correlation between net clinical benefit and all","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE1IZUVsdXFYTnpGVG5lX3hqMWFXLUR4cHVtMW9NdmhoOWlrb0V0ODVlUzRVTUlXclN6R1RTbllNZG5xTktaOFVjNHJOSEt5OFJ2UkE?oc=5","date":"2017-04-19","type":"pipeline","source":"nature.com","summary":"A sphingosine-1-phosphate receptor 1 agonist inhibits tertiary lymphoid tissue reactivation and hypersensitivity in the lung - nature.com","headline":"A sphingosine-1-phosphate receptor 1 agonist inhibits tertiary lymphoid tissue reactivation and hypersensitivity in the ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE95NWRCTE04a3lXWHc5Z1J1Q3JTVkxVTW1CR010VElYcVFCVGd6Y2xVeEJaZXl0NTBuckd2Vm9wX3hoZ295ckZOY1hCN3d4OEQ4QjZF?oc=5","date":"2016-10-18","type":"pipeline","source":"nature.com","summary":"Diversity of antibiotic-resistance genes in Canadian isolates of Aeromonas salmonicida subsp. salmonicida : dominance of pSN254b and discovery of pAsa8 - nature.com","headline":"Diversity of antibiotic-resistance genes in Canadian isolates of Aeromonas salmonicida subsp. salmonicida : dominance of","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"marketed":9},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}